Butein induces apoptosis and inhibits prostate tumor growth in Vitro and in Vivo

Antioxidants and Redox Signaling

Volumn 16, Issue 11, 2012, Pages 1195-1204

  Khan, Naghma ^a   Adhami, Vaqar M ^a   Afaq, Farrukh ^a,b   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BUTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; DNA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P110; PROTEIN P85;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CASPASES; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CHALCONES; HUMANS; MALE; MICE; MICE, NUDE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEOLYSIS;

MUS MUSCULUS;

EID: 84859860480     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4162     Document Type: Article

References (39)

1. Athar M, Back JH, Kopelovich L, Bickers DR, and Kim AL. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 486: 95-102, 2009.
2. Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C, and Peters G. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9: 71-79, 1994. (Pubitemid 24020935)
3. Ben-Neriah Y and Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12: 715-723, 2011.
4. Cantley LC. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002. (Pubitemid 34579158)
5. Ciraolo E, Morello F, and Hirsch E. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Current Med Chem 18: 2674-2685, 2011.
6. Flavin R, Zadra G, and Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 223: 283-294, 2011.
7. Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett 281: 128-133, 2009.
8. Hayden MS and Ghosh S. Shared principles in NF-kappaB signaling. Cell 132: 344-362, 2008.
9. Hennessy BT, Smith DL, Ram PT, Lu Y, and Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
10. Iwashita K, Kobori M, Yamaki K, and Tsushida T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotechnol Biochem 64: 1813-1820, 2000.
11. Jost PJ and Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109: 2700-2707, 2007. (Pubitemid 46482061)
12. Kang DG, Lee AS, Mun YJ, Woo WH, Kim YC, Sohn EJ, Moon MK, and Lee HS. Butein ameliorates renal concentrating ability in cisplatin-induced acute renal failure in rats. Biol Pharm Bull 27: 366-370, 2004. (Pubitemid 41685481)
13. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006. (Pubitemid 44050137)
14. Khan N, Adhami VM, and Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer 17: R39-R52, 2010.
15. Khan N, Afaq F, and Mukhtar H. Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett 293: 133-143, 2010.
16. Khan N, Afaq F, Syed DN, and Mukhtar H. Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells. Carcinogenesis 29: 1049-1056, 2008. (Pubitemid 351982251)
17. Khan N, Asim M, Afaq F, Abu Zaid M, and Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res 68: 8555-8563, 2008.
18. Khan N, Hadi N, Afaq F, Syed DN, Kweon MH, and Mukhtar H. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 28: 163-173, 2007. (Pubitemid 44942640)
19. Kim N. Butein sensitizes human leukemia cells to apoptosis induced by tumor necrosis factor-related apoptosis inducing ligand (TRAIL). Arch Pharm Res 31: 1179-1186, 2008.
20. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR, and Roberts JM. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257: 1689-1694, 1992.
21. Lau GT, Huang H, Lin SM, and Leung LK. Butein downregulates phorbol 12-myristate 13-acetate-induced COX-2 transcriptional activity in cancerous and non-cancerous breast cells. Eur J Pharmacol 648: 24-30, 2010.
22. Lee JC, Lee KY, Kim J, Na CS, Jung NC, Chung GH, and Jang YS. Extract from Rhus verniciflua Stokes is capable of inhibiting the growth of human lymphoma cells. Food Chem Toxicol 42: 1383-1388, 2004. (Pubitemid 38844855)
23. Lew DJ, Dulic V, and Reed SI. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 66: 1197-1206, 1991. (Pubitemid 121001409)
24. Luo J, Manning BD, and Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262, 2003. (Pubitemid 37329790)
25. Moon DO, Kim MO, Choi YH, Hyun JW, Chang WY, and Kim GY. Butein induces G(2)/M phase arrest and apoptosis in human hepatoma cancer cells through ROS generation. Cancer Lett 288: 204-213, 2010.
26. Moon DO, Kim MO, Choi YH, and Kim GY. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation. Mol Cancer Ther 9: 1583-1595, 2010.
27. Moon DO, Kim MO, Lee JD, Choi YH, and Kim GY. Butein suppresses c-Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett 286: 172-179, 2009.
28. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann Rev Cell Dev Biol 13: 261-291, 1997. (Pubitemid 28034527)
29. Pandey MK, Sung B, Ahn KS, and Aggarwal BB. Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol Pharmacol 75: 525-533, 2009.
30. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Hui KM, and Sethi G. Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 17: 1425-1439, 2011.
31. Samoszuk M, Tan J, and Chorn G. The chalcone butein from Rhus verniciflua Stokes inhibits clonogenic growth of human breast cancer cells co-cultured with fibroblasts. BMC Complement Altern Med 5: 5, 2005.
32. Sarker D, Reid AH, Yap TA, and de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15: 4799-4805, 2009.
33. Syed DN, Khan N, Afaq F, and Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 16: 2193-2203, 2007. (Pubitemid 351196348)
34. Tomayko MM and Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154, 1989. (Pubitemid 19163397)
35. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87: 652-661, 1995.
36. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993. (Pubitemid 24036020)
37. Yang EB, Zhang K, Cheng LY, and Mack P. Butein, a specific protein tyrosine kinase inhibitor. Biochem Biophys Res Commun 245: 435-438, 1998. (Pubitemid 28418520)
38. Zhang L, Chen W, and Li X. A novel anticancer effect of butein: inhibition of invasion through the ERK1/2 and NFkappa B signaling pathways in bladder cancer cells. FEBS Lett 582: 1821-1828, 2008.
39. Zhang X, Tang N, Hadden TJ, and Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 1813: 1978-1986, 2011.